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Mutations in the coding sequence of the methyl-
CpG-binding protein 2 gene (MECP2), which cause
Rett syndrome (RTT), have been found in male
and female autistic subjects without, however, a
causal relation having unequivocally been estab-
lished. In this study, theMECP2 gene was scanned
in a Portuguese autistic population, hypothesiz-
ing that the phenotypic spectrum of mutations
extends beyond the traditional diagnosis of RTT
and X-linked mental retardation, leading to a non-
lethal phenotype in male autistic patients. The
coding region, exon–intron boundaries, and the
whole 30UTR were scanned in 172 patients and 143
controls, by Detection of Virtually All Mutations-
SSCP (DOVAM-S). Exon 1 was sequenced in 103
patients. We report 15 novel variants, not found in
controls: one missense, two intronic, and 12 in the
30UTR (seven in conserved nucleotides). The
novel missense change, c.617G>C (p.G206A), was
present in one autistic male with severe
mental retardation and absence of language, and
segregates in his maternal family. This change is
located in a highly conserved residue within a
region involved in an alternative transcriptional
repression pathway, and likely alters the secon-
dary structure of the MeCP2 protein. It is there-
fore plausible that it leads to a functional
modification of MeCP2. MECP2 mRNA levels
measured in four patients with 30UTR conserved
changes were below the control range, suggesting
an alteration in the stability of the transcripts.
Our results suggest that MECP2 can play a role in
autism etiology, although very rarely, supporting
the notion thatMECP2mutations underlie several
neurodevelopmental disorders.
 2007 Wiley-Liss, Inc.
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INTRODUCTION
Mutations in the coding region of the methyl-CpG-binding
protein 2 gene (MECP2) are responsible for about 80% of Rett
Syndrome (RTT, OMIM #312750) cases [Amir et al., 1999].
Most RTT patients develop microcephaly, seizures, and
autism. Autism (OMIM #209850) is a neurodevelopmental
disorder characterized by deficits in social interaction and
communication, and by restricted and stereotyped patterns of
behavior. It affectsmoremales than females, ina ratio of 3–4:1,
which led to the hypothesis of the involvement of an X-linked
gene. As autism and RTT share a range of symptoms, it was
speculated that specificmutations in theMECP2 coding region
could also be involved in autism etiology. Evidence for linkage
to autismwas recently found at chromosome Xq27–q28, in the
region where MECP2 maps, supporting it as a candidate gene
for this disorder [Vincent et al., 2005]. So far, a number of
mutations previously found in RTT have been reported in
autism studies [vanKarnebeek et al., 2002;Carney et al., 2003;
Lobo-Menendez et al., 2003; Zappella et al., 2003]. In two
studies novel alterations were reported, one missense change
in one autistic male [Beyer et al., 2002] and a de novo intronic
variation in an autistic female with mental retardation [Lam
et al., 2000], although their functional significance was not
demonstrated. Mutations in MECP2 have also been found in
other syndromes, including non-specific X-linked mental
retardation in males (reviewed in Bienvenu and Chelly
[2006]). Although severe MECP2 mutations leading to RTT
are thought to be lethal in hemizygous males, these studies
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show the existence of sequence changes not found in RTT
that segregate in the families of males with autism,
mental retardation, and occasionally language problems.
Hemizygosity for some MECP2 mutations, leading to a less
severe functional alteration of the protein, may therefore be
compatible with life, with heterozygosity for these same
mutations insufficient to cause disease in the female carriers.
The MECP2 gene originates two protein isoforms:
MeCP2_e2, encoded by exons 2–4, and MeCP2_e1, encoded
by exons 1, 3, and 4,which ismore abundantly expressed in the
brain [Kriaucionis and Bird, 2004;Mnatzakanian et al., 2004].
MeCP2 acts as a transcriptional repressor and is mainly
expressed in the central nervous system (CNS), indicating a
role in the regulation of brain gene expression. Although its
target genes are not fully known, microarray studies have
found several genes with altered expression in RTT, some
showing a direct regulation by MeCP2 (reviewed in Bienvenu
and Chelly [2006]). In addition, it has been demonstrated that
it regulates the expression of the brain-derived neurotrophic
factor gene (BDNF), which encodes a molecule essential
in neurodevelopment and neuronal plasticity, learning, and
memory [Chen et al., 2003; Martinowich et al., 2003]. The
30UTR in exon 4 is unusually long (8.5 kb) and well conserved
between human andmouse, with at least eight blocks of strong
sequence similarity that can represent important functional
domains [Coy et al., 1999]. The size and conservation of this
region, as well as expression studies in post-mortem brain,
indicate an important role in the transcriptional regulation of
MECP2. Samaco et al. [2004] found altered levels of MECP2
expression in the brain of four out of five autistic individuals,
none of which had mutations in the coding region of MECP2,
suggesting that variations in the 50UTR or 30UTR could
be responsible for these changes. These findings support the
hypothesis that variants in the 30UTR, and not only in the
coding region of MECP2, may be involved in some clinical
manifestations.
A previous report has shown a higher frequency of missense
and 30UTR variants in a sample of 24 autistic patients, as
compared to other psychiatric diseases [Shibayama et al.,
2004]. In the present study, we extend the search for MECP2
mutations in the coding region, exon–intron boundaries, and
in the whole 30UTR in 172 patients with autism. Our goal was
to determine if the phenotypic spectrum of mutations extends
beyond the traditional diagnosis in RTT and mental retarda-
tion, leading to a less severe phenotype in autistic male and
female patients.
MATERIALS AND METHODS
Subjects and Clinical Assessments
One hundred seventy two caucasian unrelated autistic
children (141 males and 31 females; age range of 2–14 years
old), originating from mainland Portugal and the Azorean
islands, were recruited at the Autism Clinic from Hospital
Pedia´trico de Coimbra (HP). Diagnosis and assessment of the
children followed a comprehensive evaluation protocol by a
clinical team including a developmental pediatrician, two
psychologists, one special education teacher, and a social
worker. Observation of the children entailed extensive inter-
action and semi-structured activities in a clinical setting. ASD
was diagnosed using DSM-IV (American Psychiatric Associa-
tion 1994) criteria, the Autism Diagnostic Interview-Revised
(ADI-R) [Lord et al., 1994], and the Childhood Autism Rating
Scale (CARS) [Schopler et al., 1988]. Diagnosis required
fulfillment of DSM-IV criteria and meeting the ADI-R
algorithm cutoff for autistic disorder, and a functional level of
12 months or above. Consensus diagnosis among the clinical
teamwas obtained for all patients. About 90% of these patients
are routinely followed by the same clinical team at HP and
therefore are monitored over several years until age 18.
Developmental or intellectual quotients were determined
using the Ruth Griffiths Mental Development Scale II
[Griffiths, 1984] or the Wechsler Intelligence Scale for
Children (WISC 1974). Functional level was assessed using
theVinelandScales forAdaptiveBehavior [Carter et al., 1998].
Idiopathic subjectswere included after clinical assessment and
screening for knownmedical and genetic conditions associated
withautism, including testing forFragileXmutations (FRAXA
and FRAXE), chromosomal abnormalities (karyotype study),
neurocutaneous syndromes, endocrine, and metabolic dis-
orders. Control Portuguese unrelated adult individuals con-
sisted of 143 caucasian healthy blood donors (113 males and
30 females), with no family history of neuropsychiatric
diseases. Control Portuguese unrelated children consisted of
36 healthy individuals (21 males and 15 females; age range of
2–15 years old), recruited at the surgery service at the HP
where they were undergoing minor surgery procedures,
requiring blood sample collection for pre-surgery baseline
evaluation. The study was approved by the HP ethical
committee, and all participants or legal representatives signed
an informed consent.
MECP2 Mutation Detection
The coding region of MECP2 comprising exons 2–4, exon–
intron boundaries, and its whole 30UTR, were scanned for
mutations with Detection Of Virtually All Mutations-SSCP
(DOVAM-S) [Liu et al., 1999]. DOVAM-S is a robotically
enhanced and highly redundant form of Single Strand
Conformational Polymorphism (SSCP) with virtually 100%
sensitivity of mutation detection. The gene was first amplified
robotically in 42 segments ranging in size from 150 to 476 bp,
pooled, denatured, and electrophoresed under five non-
denaturing conditions varying in gel matrix, buffer, tem-
perature, and additive. PCRproductswithmobility shiftswere
sequenced with the ABI model 377 (Perkin-Elmer Model 377,
Norwalk, CT) and nucleotide alterations were analyzed with
Sequencher 4.1 software (Gene Codes, Ann Arbor, MI).
Sequence changes were confirmed by reamplification with
genomic DNA and sequencing in the opposite direction. Exon 1
was analyzed by direct sequencing of the corresponding region.
Information on the primers used for amplification of the coding
region and the 30UTR ofMECP2, as well as the PCR conditions
used, is provided on the Supplementary Information section.
Bioinformatic Analysis of the MECP2 Sequence
In order to assess if the novel intronic changeswere affecting
normal splicing by altering a consensus sequence, the program
GenScan version 1.0 was used, which performs predictions of
exon/intron splice sites based on local nucleotide sequence
properties of the genomic DNA. Protein secondary structure
predictions were performed for the novel missense changes
found in MECP2 using the programs PeptideStructure (GCG
package, version 10.0), Garnier (Emboss, version 2.8.0), and
SSpro8, which use several algorithms for prediction based on
the primary structure and properties of the amino acid
residues. Searching for sequence patterns in the 30UTR of
MECP2 was performed using UTRscan database, which looks
for known UTR functional elements, and the program
FindPatterns (GCGpackage, version 10.0),which locates short
sequence patterns specified by the user.
RNA Isolation and Quantification of the MECP2 mRNA
Total RNA was extracted from 5 106 peripheral blood
mononuclear cells (PBMCs) using the RNeasy Mini Kit
(Qiagen, Valencia, CA), and used for amplification of the first
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strand of cDNA by reverse transcription with oligo-dT primer
(Invitrogen, Carlsbad, CA). Total MECP2 mRNA (MECP2_e1
and MECP2_e2 transcripts) levels were quantified by quanti-
tative PCR with LightCycler Fast Start SYBR Green I (Roche
Molecular Biochemicals, Mannheim, Germany). For each
sample, 50 ng of first-stranded cDNA were amplified in
duplicate by PCR and real-time fluorimetric intensity of SYBR
green I was monitored. The levels of MECP2 mRNA for each
sample were normalized by the amount of mRNA of the
housekeeping gene HPRT1. Details for the quantitative PCR
reaction, including primers used for MECP2 and HPRT1 are
provided in the Supplementary Information section.
Quantitative X-chromosome Inactivation Assay
X-chromosome inactivation (XCI) assays were performed in
DNA isolated from peripheral blood leukocytes, to assess the
pattern of XCI in the carrier mother and maternal grand-
mother of the autistic male who presented the novel p.G206A
missense change. It was also performed in the proband, in
order to determinewhich allele was inherited fromhismother.
The assay was based on a previously described method
[Allen et al., 1992], which allows the determination of the X-
inactivation status using a trinucleotide repeat polymorphism
in the androgen receptor gene (AR) flanked by two methyla-
tion-sensitive restriction enzyme sites. These sites are methy-
lated on the inactive X chromosome, and are unmethylated on
the active X chromosome. This allowed the development of an
assay that distinguishes between the maternal and paternal
alleles (through the repeat number) and identifies their
methylation status (through enzymatic restriction). Details
for the assay are provided in the Supplementary Information
section.
Quantification of BDNF Levels in Plasma
Levels of BDNF were quantified in plasma using BDNF
Emax Immunoassay System kit (Promega Corp., Madison,
WI), according to the manufacturer’s instructions. The assays
were performed in duplicate for each sample.
RESULTS
Variation of the MECP2 Coding Region and
Exon–Intron Boundaries in Autistic Patients
and Controls
Scanning of MECP2 sequence changes in exons 2–4 and
exon–intron boundaries was performed in 172 patients (141
males and 31 females; 203 X-chromosomes total), revealing
that 12 patients (7.0%), 10males and 2 females, have sequence
changes corresponding to 11 different variants (Table I). Of
these, four are missense changes observed in males, of which
one is novel. In addition,we found four silent and three intronic
changes (two novel); of these, two silent and one intronic
change were also present in the controls, and have been
previously reported [Trappe et al., 2001; Kleefstra et al., 2004].
The novel missense change is a c.617G>C transition found in
one autistic male, resulting in a p.G206A amino acid replace-
ment in the inter-domain region of MeCP2, and was not found
in 143 controls. Protein secondary structure predictions
revealed that this alteration can disturb a a-helix in the
inter-domain region of the protein, due to the alteration in
amino acid properties from polar to hydrophobic. This amino
acid position is included in a region involved in a histone
deacetylase-independent pathway of transcriptional repres-
sion byMeCP2 [Yu et al., 2000], and thus this sequence change
is likely to lead to an alteration in protein function. Predictions
of exon/intron splice siteswere performed for thenovel intronic
changes found, and do not alter any putative consensus
sequence in the genomic DNA, therefore it is not likely that
they affect normal splicing of MECP2. None of the sequence
variants found in our autistic children sample have been
reported as pathogenic mutations in Rett syndrome studies.
Sequencing of exon 1 was performed in 103 autistic patients
(88 males and 15 females; 118 X-chromosomes total), and no
sequence changes were found, indicating that alterations in
this region in autistic patients are likely very rare.
In 143 Portuguese healthy controls (113 males and
30 females; 173X-chromosomes total), we found 11 individuals
(7.7%), 5 males and 6 females, with sequence changes in exons
2–4 and exon–intron boundaries, corresponding to six distinct
variants (Table II). Of these, one is a novel missense change
(p.K82R) occurring in one male, one intronic change, and four
silent changes. The p.K82Rmissense change does not lead to a
change in amino acid properties and does not alter the
secondary structure of the protein, so it likely represents a
rare polymorphism.None of the sequence variants found in the
control samples have been reported as pathogenicmutations in
previous studies. Of the sequence changes observed in
this study, three were common to both patients and controls
(c.378-19delT, p.A131A, and p.T445T), suggesting that they
are polymorphisms with no pathogenic effect, as reported
before [Trappe et al., 2001; Kleefstra et al., 2004].
Variation of the MECP2 30UTR in Autistic
Patients and Controls
Scanning of mutations was performed in the whole 30UTR of
MECP2. We found 46 patients out of 172 (26.7%) with 30UTR
variations, some having more than one change. In total,
24 unique sequence changes were found (13 in conserved
nucleotides), ofwhich 21 arenovel (Table III). In 96Portuguese
controls (76 males and 20 females; 116 X-chromosomes total)
we observed 26 individuals (27.1%)with 30UTRvariations, in a
total of 20 unique sequence changes (12 in conserved nucleo-
tides) (Table IV). Again, some of the individuals hadmore than
one sequence change, indicating that there is a high variability
in the 30UTR. All of the variations encountered were novel,
except the c.9964insC [Bourdon et al., 2001]. Ten of the
changes were common to both patients and controls, suggest-
ing that they do not have any pathogenic effect. A high degree
of sequence variability in the 30UTRwas found, comparable in
patients and controls, even in the most conserved regions
between human and mouse. However, of the 21 novel changes
found in patients, 12were not present in the controls. Of these,
seven were located in conserved nucleotides in seven autistic
males, and only one was found in one autistic female:
c.4167G>A (heterozygous). One of these novel changes,
c.1655G>A, was localized in a region of strong sequence
identity with mouse, suggesting that it may alter the regula-
tion of MECP2 expression.
Little is known about the functionality of the long 30UTR of
MECP2. In order to understand themeaning of the alterations
found in this study we performed scans for known sequence
patterns in 30UTR regions. We found eight matches for 15-
lipoxygenase differentiation control elements (15-LOX-DICE),
which are CU-rich sequences involved in mRNA stabilization
and translation inhibition, and at least two matches for AU-
rich elements (AREs) and several C-rich regions, involved in
the regulation of mRNA stability. However, none of the 30UTR
alterations found exclusively in the patients were localized
within any of these regions. MECP2 mRNA levels were
measured in PBMCs from four autistic males presenting
changes in conserved nucleotides: c.1832G>C, c.2015G>A,
c.4017T>A, and c.4417G>A (Fig. 1). MECP2 mRNA levels
measured in four autistic males in the same age range, but
without any detectedMECP2 alteration, were used as controls
for specificity of these MECP2 changes within the autistic
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phenotype. MECP2 mRNA levels of the patients with 30UTR
changes were significantly lower when compared with these
controls (Kruskal–Wallis test, P¼ 0.021). Although mRNA
levels were measured in very few individuals, all four patients
with 30UTR alterations had lower levels than any of the
patientswith noMECP2 sequence changes (Fig. 1), suggesting
that at least these alterations in 30UTR conserved nucleotides
may render the MECP2 transcripts more unstable and subject
to degradation.
Analysis of the Novel p.G206A Missense Change
Segregation analysis was carried out in the family of the
autistic male in which the novel p.G206A missense change
was found (Fig. 2A). Clinical, neuropsychological, and beha-
vioral data on this patient is shown in Table V. This patient
was10years old at the timeof collection, andhad severe autism
(positive ADI-R and DSM-IV with a CARS score of 50.5),
severe mental retardation (Global Developmental Quotient of
TABLE III. MECP2 30UTR Variants Identified in 172 Unrelated Autistic Patients
Nucleotide
changea
Nucleotide
conservationa
Number of
samples Mut/PMb References
c.1470G>A 1 PM Lam et al. [2000]
c.1554G>A Mus musculus 1 PM Ylisaukko-Oja et al. [2005]
c.1655G>A Mus musculus 1 This report
c.1832G>C Mus musculus 1 This report
c.2005G>A 1 This report
c.2015G>A Mus musculus 1 This report
c.2228G>T 1 This report
c.2322T>G Mus musculus 1 This report
c.2339C>G 15 This report
c.2829C>A Mus musculus 1 This report
c.3198G>A Mus musculus 8 This report
c.4017T>A Mus musculus 1 This report
c.4118G>A 1 This report
c.4167G>A 1 This report
c.4417G>A Mus musculus 1 This report
c.4938G>A 2 This report
c.5119C>T 1 This report
c.5339G>C 1 This report
c.6037A>C Mus musculus 1 This report
c.6948ins(AT) Mus musculus 1 This report
c.9209C>T Mus musculus 1 This report
c.9317A>C Mus musculus 13 This report
c.9964delC 2 This report
c.9964insC 3 PM Bourdon et al. [2001]
aRefSeq ID: NM_004992.2 (human), AF158181.1 (M. musculus).
bMut, mutation; PM, polymorphism.
TABLE IV. MECP2 30UTR Variants Identified in 96 Healthy Control Individuals
Nucleotide changea
Nucleotide
conservationa
Number of
samples Mut/PMb Reference
c.1854G>A 1 This report
c.1950G>C Mus musculus 1 This report
c.1990G>T Mus musculus 1 This report
c.2267G>A Mus musculus 1 This report
c.2292G>C Mus musculus 1 This report
c.2336insA 1 This report
c.2339C>G 8 This report
c.2698T>C Mus musculus 1 This report
c.3198G>A Mus musculus 5 This report
c.4938G>A 3 This report
c.5123A>G Mus musculus 1 This report
c.5339G>C 1 This report
c.5547del(GT) 1 This report
c.6037A>C Mus musculus 2 This report
c.6948ins(AT) Mus musculus 1 This report
c.7300C>T Mus musculus 1 This report
c.9209C>T Mus musculus 1 This report
c.9317A>C Mus musculus 5 This report
c.9964delC 5 This report
c.9964insC 2 PM Bourdon et al. [2001]
aRefSeq ID: NM_004992.2 (human), AF158181.1 (M. musculus).
bMut, mutation; PM, polymorphism.
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25), and absence of language. He had purposeful hand
manipulation of objects and hand stereotypies not character-
istic of Rett syndrome. Breathing irregularities were never
noticed by the family and he never had epilepsy. In the first
year of life he had developmental delay without history of
regression, the weight and height were in the percentile 5, and
the cephalic perimeter was in the percentile 50 (without
posterior deceleration of head growth). Presently 15 years old,
he shows the same symptomatology and his neurologic
examination does not show any abnormality besides mental
retardation and autistic behavior. This patient has a younger
male sibling who is 3 years of age and has a normal
development to this day. A maternal aunt died at age 7 and
was reported to have mental retardation, abnormal motor
development, and uncontrolled seizures of unknown etiology.
The available relatives from the proband were sequenced for
the p.G206A alteration: his parents, the maternal grand-
mother, and a maternal uncle (see Fig. 2A). The mother and
maternal grandmother are heterozygous asymptomatic car-
riers of this sequence change. Quantitative XCI assays were
then performed in the female relatives; the proband was also
tested, to determine which of the alleles was inherited from
his mother. A pattern of moderately skewed XCI ratio of
30%:70% was found in the mother, and a normal random
pattern of 40%:60% was found in the grandmother (Fig. 2B).
Although the three individuals (proband, mother, and mater-
nal grandmother) share the same alteration, they do not share
one common androgen receptor gene (AR) allele. Because AR
(Xq12) and MECP2 (Xq28) are located far apart in the X
chromosome, this suggests that a crossing-over event has
occurred between generations. If this is correct, the mutation
must be segregating with the lowmolecular weight allele from
the grandmother to the mother (allele c in Fig. 2B), and then
passed to the proband together with the intermediate
molecular weight allele (allele b in Fig. 2B), due to recombina-
tion in the mother’s germline. Densitometry analysis shows
that in the mother, who inherited the mutated MECP2 allele
from the grandmother (associated with allele c in Fig. 2B), the
X chromosome carrying the wild type MECP2 allele (inherited
Fig. 1. MECP2 mRNA quantification in PBMCs from four autistic males with different 30UTR alterations in conserved nucleotides:
c.1832G>C, c.2015G>A, c.4017T>A, and c.4417G>A, compared with four autistic males without MECP2 changes. Results were normalized for HPRT1
mRNA levels.
Fig. 2. Pedigree and X-chromosome inactivation (XCI) assay results in
the family of the autistic probandwho presents the novel p.G206Amissense
change inMECP2.Panel A: pedigree showing the structure of the family of
the autistic patient in whom the novel p.G206Amissense changewas found.
Panel B: XCI assay results, performed in leukocytes of the autistic proband
with the p.G206A alteration and the family female carriers; the autoradio-
graphy shows the AR allelic band pattern after PCR amplification of the
DNA samples. III.1—proband; II.3—proband’s mother; I.2—proband’s
maternal grandmother; A—PCR amplification after restriction of genomic
DNA with HhaI (only methylated, inactivated alleles are amplified); B—
PCR amplification of intact genomic DNA; C—PCR amplification with no
DNA (negative control); a, b, c—AR trinucleotide repeat alleles.
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from her father, associated with allele b in Fig. 2B), is
preferentially inactivated. Because both the mother and
maternal grandmother show a normal phenotype, any patho-
genic effect of the p.G206A missense change can likely be
compensated by the expression of the normal allele in the
carrier females.
In view of these results, we evaluated the role of the p.G206A
missense change in the functionality of MeCP2. Because
BDNF is one of the few genes known to be directly regulated
by MeCP2 [Chen et al., 2003; Martinowich et al., 2003], we
quantifiedplasmaBDNF levels in this autistic patient (19.5ng/
ml), which were found to be within normal levels when
compared to 36 age-matched control children (range: 8.9–
69.8 ng/ml; mean: 28.6 ng/ml 13.9 SD). This result suggests
that the potential pathogenic mechanism of this missense
change does not involve BDNF level changes in this patient, or
that they are too mild in plasma to be detected at this level.
DISCUSSION
In the present studywe hypothesized that sequence changes
in specific locations within the MECP2 gene that are less
deleterious forMeCP2 functionmight be involved in apathway
leading to a milder, non-lethal phenotype in autistic male and
female patients, extending beyond the traditional RTT
diagnosis.
We found low sequence variability in the coding region and
exon–intron boundaries of MECP2, comparable in autistic
patients (7.0%) and controls (7.7%), in agreement with
previous studies in which MECP2 sequence changes were
found only rarely in subjects with autism [Lam et al., 2000;
Beyer et al., 2002; van Karnebeek et al., 2002; Carney et al.,
2003; Lobo-Menendez et al., 2003; Zappella et al., 2003;
Shibayama et al., 2004]. We report two intronic variations
and one missense change that were not present in the control
sample. The novel missense change (p.G206A) was found in
one autisticmale, and segregates in his family. It is localized in
ahighly conserved amino acid,within a region implicated in an
alternative transcriptional repression pathway independent of
histone-deacetylation [Yu et al., 2000], and likely leads to a
change in protein structure, implying that it may alter the
function of MeCP2. These findings are compatible with an
association of this change with autism in the proband. In the
proband’s mother and grandmother, who have a normal
phenotype, either the MECP2 mutated allele has a low
penetrance or its deleterious effect is compensated by the
TABLE V. Clinical, Neuropsychological, and Behavioral Data of the Patient Presenting the
p.G206A Missense Change in MECP2
Variable Clinical data
Age at examination (years) 10
Physical measurements
Height 5th percentile
Occipital-frontal circumference (OFC) 50th percentile
Weight 5th percentile
Neurological symptoms
Seizures No
Brisk tendon reflexes No
Tremor No
Developmental history
First remarkable signs of autism (months) <12
Walked independently (months) 12
Motor skills
Poor-motor coordination No
Slow No
Clumsy No
Regression No
Sleep problems No
Developmental quotient (Ruth Griffiths Mental Development Scale II)
Global developmental quotient (GDQ) 25
Motor developmental quotient (MDQ) 30
Performance developmental quotient (PDQ) 23
Language developmental quotient (LDQ) 13
Vineland adaptive behavior scales domain scores
Communication (percentile ranka) 40
Daily living (percentile ranka) 50
Socialization (percentile ranka) 40
Adaptive behavior composite (percentile ranka) 50
DSM-IV positive criteria
Qualitative impairment in social interaction 3 out of 4
Qualitative impairments in communication 2 out of 4
Restricted repetitive and stereotyped patterns of behavior, interests, and
activities
4 out of 4
Delays or abnormal functioning, with onset prior to age 3 years, in social
interaction, language and symbolic or imaginative play
Yes
Disturbance not better accounted for by Rett’s disorder or CDD No
ADI-R domain scores at final diagnosis
Social interaction (cutoff¼10; max.¼30) 29 out of 30
Communication: nonverbal (cutoff¼7; max.¼ 14) 13 out of 14
Repetitive behavior (cutoff¼3; max.¼ 12) 4 out of 12
aSupplemental Norm Group percentiles ranks—Autism Special Population [Carter et al., 1998].
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expression of the normal allele, which may be sufficient to
avoid the appearance of symptoms. It is possible that the
maternal aunt, affectedwithmental retardation, andwho died
early in life, had the p.G206A alteration with a skewed
XCI favoring the expression of the mutated allele. Plasma
BDNF levels of the autistic proband were found to be within
normality, suggesting that the pathogenicmechanismdoesnot
involve BDNF level changes in this patient. However, we
cannot exclude that an alteration in BDNF levels in the CNS
mediatedby the alteredMeCP2 isnot accompanied bya change
in plasma levels. The expression of other target genes which
may be involved in the clinical phenotype of this patient was
not investigated.
We sequenced exon 1 ofMECP2 in 103 autistic patients, and
found no sequence changes in this region. Mutations in exon 1,
and thus in MeCP2_e1, either do not play a role in autism
etiology or occur very rarely associated with this disorder,
possibly with a very severe effect.
To our knowledge, this is the first report in which the whole
30UTR of MECP2 was scanned for sequence variations. We
found a high degree of sequence variability in the 30UTR,
comparable between patients (26.7%) and controls (27.1%). In
172 patients, 12 novel changes were found, of which 7 were
located in conserved nucleotides. In the patients carrying four
of these conserved 30UTR alterations MECP2 mRNA levels
were always lower that in autistic patients without any
MECP2 sequence changes. While the use of autistic indivi-
duals with no MECP2 alterations as controls does not provide
us with the normal range of mRNA levels, it suggests that
lower expression, and a consequent abnormal overexpression
of target genes, may be a specific cause of autism for the
individuals bearing theseMECP2 sequencealterations, among
autistic individuals. Given the etiological heterogeneity of
autism, with multiple genetic alterations known to lead to an
autistic phenotype, this hypothesis is plausible. These results
are however to be considered preliminary, as the sample size is
very small. If confirmed in a larger sample, these observations
would indicate the existence of important regulatory regions
within the 30UTR of MECP2.
Taken together, our results suggest that mutations in the
MECP2 coding region and 30UTR alterations in conserved
regions may play only a minor role in autism etiology. We
report a novel missense change, which may have a non-lethal
but severe pathogenic effect in males. Functional studies in
order to demonstrate its pathogenicity are under way.
Mutations in the coding region, however, are probably
restricted to a very small subgroup of subjects with autism,
aswe found only one patient out of 172 (0.58%)with a potential
pathogenic mutation; if we consider exclusively the autistic
male sample (n¼ 141), this frequency increases to 0.71%.
Additionally, we report seven novel 30UTR alterations in
conserved nucleotides, present in seven autistic males out of
172 patients (4.07%; 4.96% in the male sample), of which at
least four possibly alter the stability of theMECP2 transcripts.
The frequency of MECP2 alterations in autism might be
higher, as we did not scan the promoter region and themethod
used cannot detect large deletions or duplications that could be
missed in heterozygous females (and duplications in males).
Our patient sample included only idiopathic cases, which were
screened for common medical conditions associated with
autism including tuberous sclerosis, Fragile X syndrome, and
chromosomal abnormalities, as a standard procedure. The
prevalence of these conditions in autism spectrum disorders is
estimated to be 1–3%, 2–3%, and 5%, respectively [Rutter,
2005], with full mutations of the gene causing the Fragile X
syndrome (FMR1) observed in less than 1% of children with
autism [Lord et al., 2000]. Similarly, raremutations inMECP2
may increase the susceptibility to develop autism in aminority
of cases. Screening for MECP2 mutations in cases of autism
associated with mental retardation, particularly in males who
may have a variable phenotype, may be useful for research
purposes, to decrease genetic heterogeneity in the study
samples and thus facilitate the identification of other genes
predisposing to autism.
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